Diversified Portfolio Helps Navigate Cyclical Volatility
发布时间:2026-04-21 来源:华泰证券
Neway Valve has released its annual report,achieving revenue of RMB7.77bn(+24.53%YoY)and an attributable NP of RMB1.60bn(+38.54%YoY)for 2025.For 4Q25,revenue was RMB2.17bn(+21.44%YoY,-1.56%QoQ),the attributable NP reached RMB487mn(+48.63%YoY,+2.08%QoQ),and the recurring NP totaled RMB1.58bn(+38.32%YoY).For 2025,revenue was largely in line with our previous forecast(RMB7.77bn),while the attributable NP exceeded our expectations(RMB1.52bn).The company delivered steady growth in both revenue and attributable NP in 2025.Maintain OVERWEIGHT.
GPM/NPM have been expanding
For 2025,the company’s GPM was 39.28%(+1.18pp YoY)and the NPM was 20.86%(+2.18pp YoY).For 4Q25,the GPM reached 45.36%(+3.81pp YoY)and the NPM was 22.84%(+4.30pp YoY),demonstrating ongoing improvement in profitability.For full-year 2025,the total expense ratio was 12.52%(-0.61pp YoY),reflecting effective cost control.Specifically,the sales expense ratio was 6.45%(-0.72pp YoY)and the administrative expense ratio was 3.24%(-0.68pp YoY),both showing YoY declines.The financial expense ratio increased slightly by 0.90pp YoY to 0.27%YoY,mainly due to forex fluctuations.For 4Q25,the expense ratio rose by 2.03pp YoY to 15.76%YoY.
Prioritizing high-end product R&D with global presence
The company has established joint R&D centers in China,Italy,and the US,forming amulti-dimensional collaborative innovation network across time zones and disciplines.It is equipped with world-class valve material and engineering laboratories supported by top-tier experimental facilities to provide robust technical support.Leveraging advanced simulation technologies and R&D management systems,the company can accurately simulate valve performance under various complex operating conditions,enabling sustained product optimization and significant improvement in R&D efficiency.In 2025,the company obtained nearly 100 patents and maintains leading industry positions in high-end castings and forgings,fugitive emission control,high-temperature&high-pressure,ultra-low-temperature,and nuclear valve technologies.For full-year 2025,the R&D expense ratio was 2.56%(-0.12pp YoY),while in 4Q25 it was 3.92%(-0.13pp YoY,+2.95pp QoQ).
Earnings forecasts and valuation
As we think that the company’s global and diversified layout should drive steady earnings growth,we slightly raise our 2026/2027 attributable NP forecasts to RMB1,948/2,319mn(up by 2.04/2.62%from our previous estimates)and introduce our 2028 attributable NP forecast of RMB2,643mn,with EPS of RMB2.51/2.99/3.41.With peer companies trading at an average of 19x 2026E PE on iFind consensus,and factoring in the company’s strong international competitiveness and successful high-end product expansion that warrant avaluation premium,we value the stock at 23x 2026E PE,raising our target price to RMB57.76(previous:RMB50.96 at 26x 2025E PE).
Risks:intensified market competition;fluctuations in freight rates and exchange rates;high correlation with demand in the petrochemical industry;disappointing business expansion progress in new fields.